Press Releases Items Per Page 102550 Year None202020192018 03-31-2020 All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study 03-30-2020 Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001 03-16-2020 Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results 01-13-2020 Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients 01-08-2020 Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference
03-30-2020 Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001
